Articles tagged with Cell Therapies
A novel synthesis method enables easy linkage of therapeutic oligonucleotides to peptide markers, streamlining the process and making it more accessible and cost-effective. This breakthrough has the potential to produce more effective and targeted RNA-based drugs.
A novel study has implicated granulocyte colony-stimulating factor (G-CSF) in both bronchopulmonary dysplasia and retinopathy of prematurity, making it a promising therapeutic candidate. G-CSF deficiency was shown to protect against these diseases, suggesting wide-ranging protection.
A phase 1 clinical trial demonstrates the efficacy of third-generation anti-CD19 CAR T-cells in treating relapsed or refractory B-cell non-Hodgkin lymphomas without causing neurotoxicity. The study also shows a robust response rate of 52% and improved safety profile compared to previous CAR T-cell therapies.
A Phase I clinical trial of AT101, a new CAR T cell therapy targeting CD19 through a distinct binding mechanism, has shown a 100% complete response rate in patients with relapsed or refractory B cell non-Hodgkin's lymphoma. The treatment was found to be safe with manageable side effects and is expected to build upon the effectiveness o...
Researchers are shedding light on the molecular mechanisms underlying HIV replication and viral integration, opening new avenues for tackling the virus. Discoveries suggest that targeting the cell nucleus and harnessing innate immunity may be key to blocking viral replication and persistence.
A new method developed at Karolinska Institutet can identify unique immune cell receptors and their location in human tissue. This breakthrough could lead to the development of novel therapies for diseases such as cancer and autoimmune disorders, by pinpointing the specific immune cells responsible.
Researchers found that probiotics can limit CRC-promoting bacteria, rebalance the microbial profile, and induce targeted cancer cell death. Postbiotics derived from probiotic bacteria have also been shown to prevent CRC by limiting tumor proliferation and modulating the balance of anti-apoptotic and pro-apoptotic factors.
Researchers found that BCMA-positive extracellular vesicles (EVs) in plasma levels correlated with myeloma patient responses to belantamab-mafodotin therapy. High EV levels preceded FLC progression and were associated with mafodotin-induced eryptosis.
Researchers from the Mass General Cancer Center presented studies on psychiatric and substance use disorders as independent predictors of treatment response and outcomes in United States Veterans with Newly Diagnosed Acute Myeloid Leukemia (AML) treated with Venetoclax Combinations. Additionally, a Phase 1 Study of CAR-T-ddBCMA for the...
Researchers discovered that RvD2, a specialized proresolving lipid mediator, can alleviate established liver scarring or fibrosis. Treatment with RvD2 improved liver histopathology and increased bone marrow and blood monocytes.
Researchers at Tohoku University found that Bergmann glial cells in the cerebellar vermis regulate the volume of aggression in mice. The study suggests that adjusting glial activity in the cerebellum could lead to therapeutic strategies for managing anger and aggression.
A study by the University of the Basque Country uses game theory to establish that tumours with less cellular heterogeneity are more aggressive. The work suggests a fresh theoretical approach for new therapeutic strategies, focusing on preserving high intratumour heterogeneity.
Scientists at St. Jude Children's Research Hospital created a highly adaptable system to improve the safety and efficacy of immunotherapy for solid tumors. By adding modular chimeric cytokine receptors to CAR T cells, the therapy can target multiple types of cancer without generating significant toxicity.
A team of researchers from Texas A&M University is developing a low-cost, safe, and controlled cancer treatment using programmable bacteria. The $20 million project aims to create an efficient bacterial therapeutic that can target cancer cells with high precision, reducing side effects and costs.
A novel contamination-detection method enables faster and safer T-cell therapy production, reducing the risk for patients and speeding up treatment. The method uses cutting-edge technology to identify harmful microorganisms within 24 hours.
Researchers developed novel small molecule inhibitors of CPSF3, a key regulator of transcription termination in ovarian cancer cells. These inhibitors exhibited potent antiproliferative effects and suppressed tumor growth in vivo.
Scientists at St. Jude Children's Research Hospital validated GRP78 as a promising but complex target for CAR T-cell immunotherapy. However, they discovered that some tumors trick the immune cells into expressing GRP78, turning off their own cancer-killing ability.
Researchers investigate nanoparticles for cancer treatment, hoping to reduce side effects and improve efficacy. La-Beck's lab aims to understand the body's interaction with nanoparticles and their impact on tumor growth and immune responses.
A recent study by Harvard researchers provides an engineering approach to understanding the failure of macrophages in cancer therapies. The team found that different phenotypes exhibit different penetration into tumors, with M0 macrophages showing improved transport efficiency.
A new therapeutic, lepodisiran, has shown promising results in reducing lipoprotein(a) levels to undetectable levels for nearly one year. The study found that the medication is safe and effective in lowering Lp(a) levels by more than 94%.
A new study suggests that a PCSK9 inhibitor given every 1-3 months may effectively lower bad cholesterol levels in people with non-genetic hypercholesterolemia. The medication, recaticimab, showed similar effectiveness and safety as other PCSK9 inhibitors when administered less frequently.
Researchers at Duke University developed a CRISPR-based platform to identify genes that improve T-cell therapies for cancer treatment. They discovered BATF3, a single master regulator of the genome, which reprograms thousands of genes in T cells and greatly enhances cancer cell killing.
A novel device, ecO2, produces oxygen at the site to keep cells alive for up to a month in vitro or weeks in vivo. This innovation improves the outcomes of cell-based therapies for diseases and injuries by increasing metabolic demand.
Researchers analyzed over 314,000 cells from rheumatoid arthritis tissue to define six types of inflammation involving diverse cell types and disease pathways. The findings shed new light on the cellular causes of RA, potentially informing targeted and effective therapeutic approaches.
Researchers at UCLA have developed a new method to engineer more powerful immune cells that can potentially be used for 'off-the-shelf' cell therapy to treat challenging cancers. Gamma delta T cells with high expressions of CD16 surface marker exhibited increased ability to recognize and kill cancer cells.
Researchers have identified a crucial biological trigger of Huntington's disease, finding that methylation converts an important protein into waste. By targeting this process, they may develop effective therapies for other neurodegenerative diseases.
Researchers found that a high-sugar diet causes insulin resistance in the brain, reducing its ability to remove neuronal debris and increasing the risk of neurodegenerative diseases. This study provides insight into how obesity-inducing diets contribute to disease risk.
A new study reveals a link between the removal of the FGFR1 protein's extracellular domain and a significant decrease in tumour volume. This finding offers a potential new avenue of treatment for patients with squamous cell carcinoma of the lungs, who have shown limited success with current therapies.
Researchers have discovered that mitochondrial respiration failure leads to genetic and metabolic reprogramming of T cells, causing their functional exhaustion. However, pharmacological or genetic optimization of cellular metabolism can increase T cell longevity and functionality.
Mutations in the PIK3CA gene lead to elevated production of the PI3Ka protein, found in approximately 40% of hormone receptor-positive breast cancers. Next-generation PI3Kalpha inhibitors targeting a different region of the mutant protein show promise in overcoming resistance.
Researchers have made significant progress in understanding a pathway contributing to liver fibrosis. Paxillin has been found to play a key role in the activation of hepatic stellate cells, leading to excessive extracellular matrix production and scarring. This discovery holds promise for developing new treatments for liver fibrosis.
Researchers found that FAAH inhibition reduced breast cancer growth in immunodeficient mice and induced apoptosis of breast cancer cells. The combination of FAAH inhibitors and endocannabinoids was the most effective treatment approach.
A new tool has been developed to rapidly grow cancer-killing white blood cells, called T cells, which could advance the availability of immunotherapy. The bioreactor is 30% faster than current technologies and can be self-contained in a sterile cabinet.
Researchers have discovered a novel biomarker that enables the evaluation of near-infrared photoimmunotherapy (NIR-PIT) treatment success. The biomarker uses microbubbles to track tumor vessels and measure the effectiveness of NIR-PIT, which combines antibodies and near-infrared light to destroy cancer cells.
A collaborative study has identified key epigenetic targets for treating hepatoblastoma, the most common childhood liver cancer. The research found that the enzyme histone-lysine methyltransferase G9a plays a crucial role in epigenetic regulation and is a promising therapeutic target.
Researchers have developed a novel approach, REVeRT, to efficiently transport large genes using dual AAV vectors at the transcript level. This new method offers increased efficiency, fewer side effects, and greater flexibility compared to existing strategies.
Researchers developed a novel 'pseudo cell' formulation using self-healing microcapsule-loading exosomes to treat diverse vitreoretinal diseases. The treatment demonstrated therapeutic benefits in both murine and nonhuman primate models, offering potential for improved patient compliance.
Researchers develop a novel iNKT cell therapy approach using canine models, demonstrating improved survival and longer therapeutic effect. The platform could potentially treat human cancers with reduced risk of relapse and increased efficacy.
A new study found that ide-cel, a CAR T-cell therapy, showed similar survival outcomes for Black and white patients with multiple myeloma. Researchers hope this finding encourages the use of ide-cel in all patients with multiple myeloma.
Researchers from NUS have developed a novel magnetic gel that heals diabetic wounds by activating dormant skin cells and repairing damaged blood vessels. The treatment has shown promising results, healing wounds up to three times faster than conventional approaches.
Scientists have developed a technique to restore the function of human-derived GPCR proteins in yeast cells, which could accelerate research and lead to more effective treatments. The approach, using error-prone polymerase chain reaction, introduces random mutations that enhance protein stability and function.
Researchers develop 3D-printed device to encapsulate insulin-producing pancreatic cells and electronic sensors in the eye. The device enables cell-based therapy for Type 1 or Type 2 diabetes, eliminating the need for sutures and allowing real-time monitoring.
Researchers found amoeboid cells in pancreatic cancer produce CD73, which drives spread and weakens immune system. Blocking CD73 reduced cancer spread to liver and decreased immune cell support.
Researchers discovered that targeting TUG1 can control brain tumor growth in mice, suggesting a potential strategy to combat aggressive brain tumors. By inhibiting TUG1, the therapy significantly suppressed tumor growth and improved survival rates when combined with standard treatment.
Researchers developed a nanocapsule that reduces lactate levels and releases hydrogen peroxide, recruiting and activating immune cells to attack tumors. The approach increased immune cell activity by 2-5-fold, improving cancer immunotherapy success rates.
Macrophages produce polyamines spermidine and spermine, which benefit epithelial cells, promoting their proliferation and defense mechanisms. This "commensal metabolism" supports the efficient self-renewal of the intestinal epithelium.
A phase 2 clinical trial found that serial blood tests can identify patients who benefit from additional immunotherapies, suggesting a potential early marker of treatment response. The study also showed that ctDNA analyses correlated with tumor size and survival, making it a promising strategy for guiding therapy.
Researchers discuss lurbinectedin as a method to treat neuroendocrine tumors (NETs), with encouraging results from phase II basket studies demonstrating activity in platinum-sensitive relapsed SCLC and other malignancies. Lurbinectedin's mechanism of action involves inhibiting oncogenic transcription, promoting apoptosis and cell death.
Scientists at Temple University's Alzheimer's Center have identified a promising new therapeutic target for Alzheimer's disease: the protein ABCA7. The study found that cholesterol depletion and inflammation suppress ABCA7 levels in human brain cells, potentially contributing to disease onset.
A research team has developed a technology that selectively targets and eliminates aging cells, contributing to various inflammatory conditions. This approach represents a new paradigm for treating age-related diseases with minimal toxicity concerns.
The Keck School of Medicine of USC has received a $2 million grant from the California Institute of Regenerative Medicine to further enhance its cutting-edge cGMP Laboratory. The funding will support the adoption of advanced technologies, including an electronic quality management system and optimized cell therapy manufacturing processes.
Researchers at Northwestern University identified a new evolutionarily conserved RNAi-based form of cell death called Death Induced by Survival gene Elimination (DISE), which targets essential survival genes in cancer cells. This mechanism is ancient and effective against all cancers tested.
Scientists from Tokyo Metropolitan University have created a new polymer that can effectively transport plasmid DNA into T-cells during CAR T-cell therapy. The polymer, called PAMAM-G2-Gu, is stable, non-toxic, and doesn't use viruses, making it a promising candidate for next-gen gene carriers.
A special supplement presents insights on neurodegenerative diseases, including Alzheimer's and Parkinson's, affecting 55 million people worldwide. Researchers explore novel molecular pathways and therapeutic approaches, such as acupuncture therapy, to alleviate the burden of brain disorders.
A team of scientists has developed a method to detect active Cullin-RING ligases (CRLs), which are responsible for destroying unwanted proteins in cells. The new technology, called a molecular radar, reveals which CRLs are deployed to address cellular stresses and perform the actions of some anti-cancer drugs.
Researchers explore kinase inhibitors as targeted therapies for specific CRC subsets, offering hope for improved treatment options. Key findings suggest that uncovering essential kinases for tumor growth can lead to more effective treatment strategies in metastatic or later-stage CRC patients.
Researchers from MedUni Vienna developed a new approach to fighting resistant cell lines in small cell lung cancer by combining two already available therapeutic agents. The study reveals the molecular mechanism underlying therapy resistance and provides a promising basis for research into successful new therapies.
A new model for producing human brown fat cells in vitro has been developed, providing a potential solution for treating obesity and type 2 diabetes. The researchers identified key cellular signaling cues that lead to brown adipocyte formation and successfully reproduced this process in human pluripotent stem cells.
Researchers found that DPP4 inhibition increased sunitinib efficacy in RCC spheroids and upregulated DPP4 in sunitinib-resistant cells. This suggests potential repurposing of DPP4 inhibitors to target therapy resistance in renal cell carcinoma.
Researchers developed a DNA damage-induced senescence model in osteoarthritic chondrocytes, which reliably induces cellular senescence and accumulates senescent cells in OA joint tissues. The study provides a useful model to develop therapeutic approaches targeting senescence in osteoarthritis.